Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial-Reference-Cited by-同舟云学术

Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial

Published:2019-04-04 Issue:11 Volume:104 Page:2265-2273
ISSN:0390-6078
Container-title:Haematologica
language:en
Short-container-title:Haematologica

Author:

Wester Ruth,van der Holt Bronno,Asselbergs Emelie,Zweegman Sonja,Kersten Marie Jose,Vellenga Edo,van Marwijk Kooy Marinus,de Weerdt Okke,Minnema Monique,Lonergan Sarah,Palumbo Antonio,Lokhorst Henk,Broijl Annemiek,Sonneveld Pieter

Publisher

Ferrata Storti Foundation (Haematologica)

Subject

Hematology

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of staging in multiple myeloma;Expert Review of Hematology;2023-11-03

2. Response adaptive salvage with KTd and ASCT for functional high‐risk multiple myeloma—The Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial;British Journal of Haematology;2023-06-18

3. Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial;The Lancet Haematology;2023-02

4. Network Modelling Methods for Precision Medicine;Systems Biology Modelling and Analysis;2022-11-18

5. What’s Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma;Targeted Oncology;2022-06-30